See more : Solar Integrated Roofing Corporation (SIRC) Income Statement Analysis – Financial Results
Complete financial analysis of HOOKIPA Pharma Inc. (HOOK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HOOKIPA Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- PT Nusantara Inti Corpora Tbk (UNIT.JK) Income Statement Analysis – Financial Results
- Sona BLW Precision Forgings Limited (SONACOMS.BO) Income Statement Analysis – Financial Results
- SF Urban Properties AG (0QN6.L) Income Statement Analysis – Financial Results
- Shekel Brainweigh Ltd. (SBW.AX) Income Statement Analysis – Financial Results
- Aura Energy Limited (AEE.AX) Income Statement Analysis – Financial Results
HOOKIPA Pharma Inc. (HOOK)
About HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 20.13M | 14.25M | 18.45M | 19.58M | 11.94M | 7.63M | 0.00 |
| Cost of Revenue | 3.55M | 3.60M | 4.64M | 53.13M | 46.31M | 21.97M | 398.00K |
| Gross Profit | 16.58M | 10.65M | 13.81M | -33.55M | -34.37M | -14.34M | -398.00K |
| Gross Profit Ratio | 82.35% | 74.72% | 74.85% | -171.31% | -287.81% | -187.91% | 0.00% |
| Research & Development | 86.42M | 68.65M | 82.85M | 54.79M | 46.31M | 21.97M | 9.77M |
| General & Administrative | 18.63M | 18.76M | 17.27M | 18.08M | 16.72M | 6.84M | 4.39M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.63M | 18.76M | 17.27M | 18.08M | 16.72M | 6.84M | 4.39M |
| Other Expenses | 0.00 | -392.00K | -2.84M | 3.07M | 601.00K | 133.00K | -25.00K |
| Operating Expenses | 117.82M | 87.40M | 100.12M | 72.87M | 63.03M | 23.20M | 12.09M |
| Cost & Expenses | 117.82M | 87.40M | 100.12M | 72.87M | 63.03M | 23.20M | 12.09M |
| Interest Income | 5.29M | 8.24M | 27.00K | 9.20M | 1.59M | 0.00 | 0.00 |
| Interest Expense | 317.00K | 687.00K | 898.00K | 786.00K | 877.00K | 778.00K | 606.00K |
| Depreciation & Amortization | 3.55M | 3.60M | 4.64M | 4.15M | 3.07M | 640.00K | 398.00K |
| EBITDA | -77.34M | -60.40M | -70.13M | -39.15M | -39.09M | -14.80M | -13.76M |
| EBITDA Ratio | -384.24% | -513.40% | -442.73% | -272.08% | -427.78% | -193.93% | 0.00% |
| Operating Income | -97.69M | -73.16M | -81.67M | -53.29M | -51.09M | -21.18M | -14.16M |
| Operating Income Ratio | -485.34% | -513.40% | -442.73% | -272.08% | -427.78% | -277.62% | 0.00% |
| Total Other Income/Expenses | 16.48M | 8.47M | 6.01M | 9.20M | 8.05M | 4.97M | 1.44M |
| Income Before Tax | -81.21M | -64.92M | -75.67M | -44.08M | -43.04M | -16.21M | -12.72M |
| Income Before Tax Ratio | -403.46% | -455.58% | -410.15% | -225.09% | -360.38% | -212.52% | 0.00% |
| Income Tax Expense | 368.00K | 230.00K | 1.00K | -10.28M | -8.89M | 24.00K | 4.00K |
| Net Income | -81.58M | -64.92M | -75.67M | -44.08M | -43.04M | -16.24M | -12.72M |
| Net Income Ratio | -405.29% | -455.58% | -410.15% | -225.09% | -360.38% | -212.83% | 0.00% |
| EPS | -8.63 | -9.90 | -23.00 | -16.90 | -2.41 | -0.99 | -0.78 |
| EPS Diluted | -8.63 | -9.90 | -23.00 | -16.90 | -2.41 | -0.99 | -0.78 |
| Weighted Avg Shares Out | 9.45M | 6.56M | 3.29M | 2.61M | 17.86M | 16.32M | 16.32M |
| Weighted Avg Shares Out (Dil) | 9.45M | 6.56M | 3.29M | 2.61M | 17.86M | 16.32M | 16.32M |
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
Source: https://incomestatements.info
Category: Stock Reports